Inotropic Agents & Heart Disease

Inotropic agents alter the force or energy of muscular contractions. Negatively inotropic agents weaken the force of muscular contractions. Positively inotropic agents increase the strength of muscular contraction. Inotropic agents are used in hospitalized patients with acute decompensated heart failure, with reduced left ventricular ejection fraction and with signs of end-organ dysfunction in the setting of a low cardiac output, or with severe systolic heart failure awaiting heart transplant to maintain hemodynamic stability or as a bridge to decision. Discover the latest research on inotrpic agents and heart diseases here.

October 27, 2020
Review

Inotropic Agents and Vasopressors in the Treatment of Cardiogenic Shock

Current Heart Failure Reports
Amanda ShabanaPrithwish Banerjee
October 15, 2020
Open Access

Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format

Stem Cell Reports
Ingra MannhardtThomas Eschenhagen
October 22, 2020

Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Circulation
Milton PackerEMPEROR-Reduced Trial Committees and Investigators
October 2, 2020
Preprint
Open Access

Human hypertrophic cardiomyopathy mutation R712L suppresses the working stroke of cardiac myosin and can be rescued by omecamtiv mecarbil

BioRxiv : the Preprint Server for Biology
A. SnobergerE. Michael Ostap
October 21, 2020

Effectiveness of Levosimendan in an 84-Year-Old Patient with Takotsubo Syndrome Complicated by Acute Heart Failure

The American Journal of Case Reports
Małgorzata Zalewska-AdamiecSławomir Dobrzycki
October 23, 2020
Open Access

Glycoside scutellarin enhanced CD-MOF anchoring for laryngeal delivery

Acta Pharmaceutica Sinica. B
Kena ZhaoJiwen Zhang
October 7, 2020

Cardiac eigen imaging: a novel method to isolate cardiac activity in thoracic electrical impedance tomography

Physiological Measurement
Saaid H ArshadRyan J Halter
October 26, 2020

Screening of medicinal herbs for cytotoxic activity to leukemia cells

Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
Bui Thi Kim LyHoang Thanh Chi
October 24, 2020

Chemical structure and antioxidant activity of a polysaccharide from Siraitia grosvenorii

International Journal of Biological Macromolecules
Yong-Ming ZhuChun-Yu Liu
October 14, 2020
Preprint
Open Access

Is Tocilizumab an effective therapy for Severe COVID-19: a retrospective cohort study

ResearchSquare
Samreen SarfarazFatima Kanani
October 8, 2020
Open Access

Availability, Costs and Stock-Outs of Essential NCD Drugs in Three Rural Rwandan Districts

Annals of Global Health
Jean Paul MukundiyukuriBethany Hedt-Gauthier
October 14, 2020

Acute heart failure

Ugeskrift for laeger
Johannes GrandChristian Hassager
October 14, 2020
Preprint
Open Access

Characterization, and Anti-microbial Properties of Zinc Oxide Nanoparticles Synthesized Using Citrus sinensis (L.) Osbeck Peel Extract

BioRxiv : the Preprint Server for Biology
D. P. KhanalSamyam Aryal
October 7, 2020

Comparing Spatially Distributed and Single Electrode Stimulation on Individuals with Spinal Cord Injury

Annual International Conference of the IEEE Engineering in Medicine and Biology Society
Lucas De Macedo PinheiroAntonio Padilha Lanari Bo
October 7, 2020
Open Access

Motor unit filter prelearning strategies for decomposition of compound muscle action potentials in high-density surface electromyograms

Annual International Conference of the IEEE Engineering in Medicine and Biology Society
A Holobar, A Francic

Sign up to follow this feed and discover related papers.

Related Feeds

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused as a result of a partial deletion of chromosome 22. Here is the latest research.

Alagille Syndrome

Alagille syndrome is a multi-system genetic disorder that can affect the liver, heart, and other parts of the body. It’s characterization includes heart problems, liver damage, jaundice, and xanthomas. Here is the latest research.

Aneurysm

Aneurysms are outward distensions or bulges that occurs in a weakened wall of blood vessels. Discover the latest research on aneurysms here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Aortic Aneurysm

An aortic aneurysm is the weakening and bulging of the blood vessel wall in the aorta. This causes dilatation of the aorta, which is usually asymptomatic but carries the risk of rupture and hemorrhage. Find the latest research on aortic aneurysms here.

Aortic Coarctation

Aortic coarctation is a congenital condition characterized by narrowing of the aorta. Discover the latest research on this disease here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

© 2020 Meta ULC. All rights reserved
/feed-previews/inotropic-agents-heart-disease/ac3dcd52-2258-4b2c-b6cc-2ab2f99bae46